NEW YORK--(BUSINESS WIRE)--Mercer, a global consulting leader in advancing health, wealth and career, and a wholly owned subsidiary of Marsh & McLennan Companies (NYSE: MMC), has appointed Jeff Dobro as the US Clinical Services and Innovation Strategy Leader. In this role he will be responsible for Mercer’s clinical consulting team and health strategy development. Dr. Dobro will report to Jean Moore, US Health Specialty and Innovation Leader.
“We are very pleased to welcome Jeff to Mercer,” said Ms. Moore, “He is one of the most highly regarded strategists and physicians in our industry and his experience in various healthcare consulting leadership roles will be a valuable addition to our team as we help clients strengthen and transform their health benefit and employee well-being programs.”
Prior to joining Mercer, Dr. Dobro was the Chief Medical Officer at One Medical. Before that, he spent six years as the Chief Medical Officer for RedBrick Health and six years as a consultant at Willis Towers Watson. Dr. Dobro is a board certified internist and rheumatologist and an Associate Professor at NYU School of Medicine. He earned his Doctor of Medicine from Drexel.
Mercer delivers advice and technology-driven solutions that help organizations meet the health, wealth and career needs of a changing workforce. Mercer’s more than 23,000 employees are based in 44 countries and the firm operates in over 130 countries. Mercer is a wholly owned subsidiary of Marsh & McLennan Companies (NYSE: MMC), the leading global professional services firm in the areas of risk, strategy and people. With nearly 65,000 colleagues and annual revenue over $14 billion, through its market-leading companies including Marsh, Guy Carpenter and Oliver Wyman, Marsh & McLennan helps clients navigate an increasingly dynamic and complex environment. For more information, visit www.mercer.com. Follow Mercer on Twitter @Mercer.